These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21396901)

  • 1. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose.
    Klugman KP; Madhi SA; Adegbola RA; Cutts F; Greenwood B; Hausdorff WP
    Vaccine; 2011 Apr; 29(18):3372-3. PubMed ID: 21396901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens.
    Mahon BE; Hsu K; Karumuri S; Kaplan SL; Mason EO; Pelton SI; ;
    Vaccine; 2006 Mar; 24(14):2514-20. PubMed ID: 16417951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers.
    Goldblatt D; Southern J; Ashton L; Richmond P; Burbidge P; Tasevska J; Crowley-Luke A; Andrews N; Morris R; Borrow R; Cartwright K; Miller E
    Pediatr Infect Dis J; 2006 Apr; 25(4):312-9. PubMed ID: 16567982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose.
    van Westen E; Rodenburg GD; van Gils EJ; Tcherniaeva I; Berbers GA; Cowell L; Goldblatt D; Rots NY; van den Dobbelsteen GP; Sanders EA
    Vaccine; 2013 Dec; 31(49):5834-42. PubMed ID: 24120678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 13-valent pneumococcal conjugate vaccine.
    Prescrire Int; 2011 Jan; 20(112):5-7, 9. PubMed ID: 21462782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics.
    Rose MA; Gruendler M; Schubert R; Kitz R; Schulze J; Zielen S
    Vaccine; 2009 Aug; 27(38):5259-64. PubMed ID: 19576944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
    Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
    Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method.
    Rückinger S; van der Linden M; Reinert RR; von Kries R
    Vaccine; 2010 Jul; 28(31):5012-6. PubMed ID: 20546832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine.
    Huebner RE; Mbelle N; Forrest B; Madore DV; Klugman KP
    Vaccine; 2004 Jul; 22(21-22):2696-700. PubMed ID: 15246599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children.
    Kilpi T; Ahman H; Jokinen J; Lankinen KS; Palmu A; Savolainen H; Grönholm M; Leinonen M; Hovi T; Eskola J; Käyhty H; Bohidar N; Sadoff JC; Mäkelä PH;
    Clin Infect Dis; 2003 Nov; 37(9):1155-64. PubMed ID: 14557958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
    Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunogenicity and reactogenicity of DTPa-IPV-HBV/Hib and DTPa-IPV/Hib vaccines coadministered with 7-valent pneumococcal conjugate vaccine as primary vaccination and booster in healthy infants, according to the French vaccination calendar].
    Reinert P; Dejos V; Clyti N; Abitbol V
    Arch Pediatr; 2008 Mar; 15(3):263-70. PubMed ID: 18272353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy.
    Dagan R; Givon-Lavi N; Greenberg D; Fritzell B; Siegrist CA
    J Infect Dis; 2010 May; 201(10):1570-9. PubMed ID: 20384496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.
    Madhi SA; Adrian P; Kuwanda L; Jassat W; Jones S; Little T; Soininen A; Cutland C; Klugman KP
    Vaccine; 2007 Mar; 25(13):2451-7. PubMed ID: 17023095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.